Company intelligence / Profile preview
Odylia Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Odylia Therapeutics is a nonprofit biotech leveraging an Anc80 AAV vector-based gene therapy platform to develop treatments for rare inherited retinal and sensory disorders. They have three internal preclinical to IND-enabling programs and support over 15 external partner programs through their Brydge Solutions initiative, focusing on ultra-orphan indications often overlooked by traditional pharma due to market size.
- Therapeutic areas
- OphthalmologyRare Diseases
- Modalities
- Gene therapyRecombinant proteinViral vector
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Odylia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Odylia Therapeutics.